Valeant Pharmaceuticals Intl Receives Average Recommendation of “Buy” from Analysts (NYSE:VRX)
Valeant Pharmaceuticals Intl (NYSE:VRX) has earned a consensus rating of “Buy” from the nineteen brokerages that are currently covering the stock, American Banking & Market News reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $148.00.
A number of research firms have recently commented on VRX. Analysts at Zacks downgraded shares of Valeant Pharmaceuticals Intl from an “outperform” rating to an “underperform” rating in a research note on Wednesday. They now have a $101.00 price target on the stock. Separately, analysts at Susquehanna cut their price target on shares of Valeant Pharmaceuticals Intl to $160.00 in a research note on Friday, August 1st. Finally, analysts at Piper Jaffray cut their price target on shares of Valeant Pharmaceuticals Intl from $151.00 to $135.00 in a research note on Friday, August 1st.
Valeant Pharmaceuticals Intl (NYSE:VRX) opened at 109.17 on Tuesday. Valeant Pharmaceuticals Intl has a 1-year low of $95.28 and a 1-year high of $153.10. The stock’s 50-day moving average is $121.1 and its 200-day moving average is $130.0. The company’s market cap is $36.617 billion.
Valeant Pharmaceuticals Intl (NYSE:VRX) last posted its quarterly earnings results on Thursday, July 31st. The company reported $1.91 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.91. The company had revenue of $1.99 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the previous year, the company posted $1.34 earnings per share. The company’s revenue for the quarter was up 86.2% on a year-over-year basis. On average, analysts predict that Valeant Pharmaceuticals Intl will post $7.99 earnings per share for the current fiscal year.
Valeant Pharmaceuticals International, Inc, formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.